Gemitrol NS Nasal Solution contains Calcitonin (Salmon) at a concentration of 200 IU per dose and is indicated for the management of conditions related to calcium metabolism, including osteoporosis, Paget’s disease of bone, and hypercalcemia associated with malignancy. Calcitonin, a polypeptide hormone, acts by inhibiting osteoclastic bone resorption, thereby reducing serum calcium levels and promoting bone mineralization. Administered intranasally, Gemitrol NS offers a non-invasive route that facilitates systemic absorption while minimizing gastrointestinal side effects commonly associated with oral therapies. The nasal solution is typically prescribed as a daily dose, with administration alternating between nostrils to reduce local irritation. Clinical studies have demonstrated its efficacy in increasing bone density and alleviating bone pain in affected patients. Adverse effects are generally mild and may include nasal dryness, irritation, or occasional sneezing. Contraindications include hypersensitivity to calcitonin or any component of the formulation. Caution is advised in patients with known hypersensitivity to fish proteins, as the active ingredient is derived from salmon. Gemitrol NS Nasal Solution should be used under medical supervision, with periodic monitoring of serum calcium levels and assessment of therapeutic response to optimize treatment outcomes.